LOXL2 and central nervous system cancer: Especially in glioma, the expression intensity of LOXL2 is significantly correlated with the clinical outcome of patients, and its mechanism of action may involve biological processes such as tumor microenvironment remodeling and immune cell infiltration regulation (17, 18).